Extracellular vesicles (EVs) are the common designation for ectosomes, microparticles and microvesicles serving dominant roles in intercellular communication. Both viable and dying cells release EVs to the extracellular environment for transfer of...
Read More »Study investigates whether adipose tissue is the source of inflammatory factors that aggravate COVID-19
There is growing evidence that adipose tissue plays a key role in the aggravation of COVID-19. One of the theories under investigation is that fat cells (adipocytes) act as a reservoir for SARS-CoV-2 and...
Read More »Exosome-mediated mRNA delivery for SARS-CoV-2 vaccination
In less than a year from its zoonotic entry into the human population, SARS-CoV-2 has infected more than 45 million people, caused 1.2 million deaths, and induced widespread societal disruption. Leading SARS-CoV-2 vaccine candidates immunize with the viral spike protein ...
Read More »COVID-19 and extracellular vesicles – an intriguing interplay
The outbreak of severe acute respiratory syndrome β-coronavirus 2 (SARS-CoV-2) has the potential to become a long-lasting global health crisis. The number of people infected with the novel...
Read More »Allele Biotech’s dual COVID vaccine packaged in iPSCs and delivered in exosomes
Allele Biotechnology and Pharmaceuticals, Inc. has been using mRNA as its core technology for creating cGMP-grade iPSC (induced pluripotent stem cells)...
Read More »Mesenchymal Stem Cell Derived Exosomes – a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19
The recent pandemic situation transpired due to coronavirus novel strain SARS-CoV-2 has become a global concern. This human coronavirus (HCov-19) has put the world on high alert as the numbers of confirmed cases are continuously increasing. The world is now ...
Read More »Dangerous rise in sale of Unsubstantiated and unlicensed stem cell and exosome treatments for COVID-19
COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has in a matter of months become a devastating global pandemic and public health emergency...
Read More »Codiak BioSciences Collaborates with Ragon Institute to evaluate the exoVACC™ vaccine platform in SARS-CoV-2 and HIV
Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the ...
Read More »Codiak presents new preclinical data demonstrating potential of engEx™ engineered exosomes to drive new class of molecular medicines
Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced new preclinical...
Read More »